NO2516457T3 - - Google Patents

Info

Publication number
NO2516457T3
NO2516457T3 NO10791039A NO10791039A NO2516457T3 NO 2516457 T3 NO2516457 T3 NO 2516457T3 NO 10791039 A NO10791039 A NO 10791039A NO 10791039 A NO10791039 A NO 10791039A NO 2516457 T3 NO2516457 T3 NO 2516457T3
Authority
NO
Norway
Application number
NO10791039A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43601078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2516457(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2516457T3 publication Critical patent/NO2516457T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
NO10791039A 2009-12-21 2010-12-17 NO2516457T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28856209P 2009-12-21 2009-12-21
PCT/US2010/060925 WO2011084664A1 (en) 2009-12-21 2010-12-17 HUMANIZED FCγ R MICE

Publications (1)

Publication Number Publication Date
NO2516457T3 true NO2516457T3 (de) 2018-08-11

Family

ID=43601078

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10791039A NO2516457T3 (de) 2009-12-21 2010-12-17

Country Status (27)

Country Link
US (9) US8658154B2 (de)
EP (4) EP3498730B1 (de)
JP (4) JP5595517B2 (de)
KR (4) KR101973524B1 (de)
CN (2) CN102762590B (de)
AU (3) AU2010339863B2 (de)
CA (2) CA2784953C (de)
CY (1) CY1120316T1 (de)
DK (2) DK2516457T3 (de)
ES (2) ES2671188T3 (de)
FI (1) FI3498730T3 (de)
HK (1) HK1257001A1 (de)
HR (2) HRP20260349T1 (de)
HU (1) HUE038684T2 (de)
IL (4) IL220365A (de)
LT (2) LT2516457T (de)
MY (1) MY156743A (de)
NO (1) NO2516457T3 (de)
PL (2) PL3498730T3 (de)
PT (2) PT2516457T (de)
RS (2) RS57280B1 (de)
RU (1) RU2549695C2 (de)
SG (3) SG181690A1 (de)
SI (2) SI3498730T1 (de)
SM (2) SMT202600074T1 (de)
TR (1) TR201808011T4 (de)
WO (1) WO2011084664A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3498730B1 (de) * 2009-12-21 2026-01-28 Regeneron Pharmaceuticals, Inc. Mäuse mit humanisiertem fc-gamma-r
SI2818478T1 (sl) 2011-10-28 2017-07-31 Regeneron Pharmaceuticals, Inc. Humanizirani il-6 in receptor il-6
BR112014007946A2 (pt) * 2011-11-01 2017-04-11 Roche Glycart Ag animal transgênico não humano, descendente, linhagem de células, explante, utilização, método para a determinação da eficácia de um anticorpo e método para a avaliação do risco potencial da segurança dos anticorpos terapêuticos
DK4389764T3 (da) * 2012-11-05 2026-04-13 Regeneron Pharma Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf
ES2681622T3 (es) 2013-09-18 2018-09-14 Kymab Limited Métodos, células y organismos
JP6492095B2 (ja) * 2013-10-15 2019-03-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化ｉｌ−１５動物
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
AU2015230938C1 (en) * 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
RS60398B1 (sr) * 2014-04-08 2020-07-31 Regeneron Pharma Ne-humane životinje sa humanizovanim fc-gama receptorima
ES2691529T3 (es) 2014-05-30 2018-11-27 Regeneron Pharmaceuticals, Inc. Animales con dipeptidil peptidasa iv (dpp4) humanizada
ES2841353T3 (es) 2014-12-09 2021-07-08 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado
ES2950399T3 (es) * 2015-04-13 2023-10-09 Regeneron Pharma Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos
US20180295818A1 (en) * 2015-04-30 2018-10-18 Institute Of Immunology Co., Ltd. TRANSGENIC NON-HUMAN ANIMAL EXPRESSING HUMAN SPECIFIC MOLECULE AND HUMAN FCy RECEPTOR FAMILY
SG10202102885UA (en) 2016-05-20 2021-05-28 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide rnas
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
IL277355B2 (en) 2018-03-26 2025-01-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
JP6935383B2 (ja) * 2018-09-27 2021-09-15 公益財団法人実験動物中央研究所 免疫不全マウス
CN116121302A (zh) * 2018-09-27 2023-05-16 公益财团法人实验动物中央研究所 免疫缺陷小鼠
BR112021016173A2 (pt) 2019-02-22 2021-11-03 Regeneron Pharma Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
US20220192166A1 (en) * 2019-03-28 2022-06-23 Central Institute For Experimental Animals Immunodeficient rodent
EP4262373A1 (de) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mäuse, die humanisierte fc-alpha rezeptoren exprimieren
CN114410643B (zh) * 2021-02-02 2024-08-02 百奥赛图(北京)医药科技股份有限公司 FcRn基因人源化的非人动物及其构建方法和应用
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE321134T1 (de) 1988-05-27 2006-04-15 Applied Research Systems Menschlicher fc-gamma-rezeptor iii
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5258359A (en) * 1991-08-02 1993-11-02 Monsanto Company Glyphosant-containing herbicidal compositions comprising acetylenic diol rainfastness enhancing agents
EP0663952A4 (de) 1992-09-11 1997-06-11 Univ California Transgene nicht-humane tiere mit zielgerichtet unterbrochenen transduktionsgenen in lymphozyten.
US5877396A (en) 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
EP1972194A1 (de) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgene Säugetiere mit menschlichen IG-Orten mit mehreren VH- und VK-Regionen und darin erzeugten Antikörpern
US5899312A (en) * 1997-07-22 1999-05-04 Lucent Technologies Inc Anti-fraud string grabbing device
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
WO2002006633A1 (en) 2000-07-18 2002-01-24 The Charles Machine Works, Inc. Remote control for a drilling machine
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
FR2822161B1 (fr) 2001-03-15 2003-09-19 Genoway Cellule et animal transgenique modelisant les reponses humaines allergiques mediees par les ige, et leurs utilisations
JP4653915B2 (ja) 2001-10-29 2011-03-16 独立行政法人科学技術振興機構 全身性エリテマトーデスモデル非ヒト動物
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DE60318065T2 (de) 2002-06-07 2008-11-20 Trillium Therapeutics Inc., Toronto Fcyriia-transgenes tiermodell für autoimmunkrankheit
JP2004147535A (ja) 2002-10-29 2004-05-27 Japan Science & Technology Agency ギラン・バレー症候群及び／又はフィッシャー症候群発症モデル非ヒト動物
WO2004060053A2 (en) * 2002-12-16 2004-07-22 Genentech, Inc. Transgenic mice expressing human cd20
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
JP4762156B2 (ja) * 2004-01-12 2011-08-31 アプライド モレキュラー エボリューション，インコーポレイテッド Ｆｃ領域変異体
EP1802193B1 (de) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Verfahren zur erzeugung einer für eine genetische modifikation homozygoten maus
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
JP2009529331A (ja) 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
US8323653B2 (en) * 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
HU0700534D0 (en) * 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
JP5588865B2 (ja) 2007-07-31 2014-09-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｃｄ２０に対するヒト抗体及びその使用方法
KR20100103810A (ko) * 2007-12-10 2010-09-28 알리바 바이오파마수티컬스, 아이엔씨. 동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법
EP2262898B1 (de) 2008-03-07 2018-01-24 Regeneron Pharmaceuticals, Inc. Von es-zellen abstammende mäuse aus der injektion eines diploiden wirtsembryos
EP2318439A2 (de) * 2008-07-23 2011-05-11 Rappaport Family Institute for Research in the Medical Sciences Verfahren zur änderung peripherer b-zellen-populationen und anwendungen davon
EP3498730B1 (de) 2009-12-21 2026-01-28 Regeneron Pharmaceuticals, Inc. Mäuse mit humanisiertem fc-gamma-r
US8883496B2 (en) * 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice

Also Published As

Publication number Publication date
CN102762590B (zh) 2015-11-25
CY1120316T1 (el) 2019-07-10
SG10202011814TA (en) 2021-01-28
IL261257B (en) 2019-12-31
IL271083A (en) 2020-01-30
CA3000246C (en) 2021-05-25
JP2014132909A (ja) 2014-07-24
US20120260357A1 (en) 2012-10-11
CN104232589A (zh) 2014-12-24
FI3498730T3 (fi) 2026-03-12
IL220365A (en) 2016-11-30
JP2016093201A (ja) 2016-05-26
RS67844B1 (sr) 2026-03-31
AU2014210646B2 (en) 2016-06-23
DK3498730T3 (da) 2026-02-23
US20140157445A1 (en) 2014-06-05
KR102178064B1 (ko) 2020-11-12
IL261257A (en) 2018-10-31
RS57280B1 (sr) 2018-08-31
CN104232589B (zh) 2018-04-27
SI2516457T1 (en) 2018-08-31
HRP20260349T1 (hr) 2026-04-24
JP2014209923A (ja) 2014-11-13
HK1257001A1 (en) 2019-10-11
IL220365A0 (en) 2012-08-30
AU2010339863A1 (en) 2012-07-12
KR101862277B1 (ko) 2018-06-01
US8658853B2 (en) 2014-02-25
CA2784953A1 (en) 2011-07-14
CA2784953C (en) 2018-05-22
US20240424145A1 (en) 2024-12-26
IL242719A (en) 2017-09-28
MY156743A (en) 2016-03-31
JP6073840B2 (ja) 2017-02-01
US8658154B2 (en) 2014-02-25
KR20120102138A (ko) 2012-09-17
JP5595517B2 (ja) 2014-09-24
US12036288B2 (en) 2024-07-16
LT3498730T (lt) 2026-03-25
US9687566B2 (en) 2017-06-27
SMT202600074T1 (it) 2026-03-09
US10426848B2 (en) 2019-10-01
PL3498730T3 (pl) 2026-04-07
US20110154512A1 (en) 2011-06-23
SG181690A1 (en) 2012-07-30
EP2516457A1 (de) 2012-10-31
US20200061213A1 (en) 2020-02-27
LT2516457T (lt) 2018-06-11
KR102092744B1 (ko) 2020-03-24
PT2516457T (pt) 2018-06-12
KR20180058860A (ko) 2018-06-01
AU2014210645A1 (en) 2014-08-28
EP4706388A3 (de) 2026-06-03
HRP20180911T1 (hr) 2018-07-13
ES3062012T3 (en) 2026-04-08
HUE038684T2 (hu) 2018-11-28
US11020495B2 (en) 2021-06-01
RU2549695C2 (ru) 2015-04-27
DK2516457T3 (en) 2018-06-18
ES2671188T3 (es) 2018-06-05
CA3000246A1 (en) 2011-07-14
US20210346522A1 (en) 2021-11-11
SG10201408415PA (en) 2015-01-29
KR20200033981A (ko) 2020-03-30
US9056130B2 (en) 2015-06-16
AU2014210645B2 (en) 2016-05-19
KR20190045404A (ko) 2019-05-02
AU2014210646A1 (en) 2014-08-28
EP2516457B1 (de) 2018-03-14
EP3336102A3 (de) 2018-08-01
JP5891259B2 (ja) 2016-03-22
SMT201800296T1 (it) 2018-07-17
WO2011084664A1 (en) 2011-07-14
EP2516457B9 (de) 2021-09-29
AU2010339863B2 (en) 2014-07-17
CN102762590A (zh) 2012-10-31
US20150313195A1 (en) 2015-11-05
TR201808011T4 (tr) 2018-06-21
SI3498730T1 (sl) 2026-03-31
JP2013514778A (ja) 2013-05-02
PL2516457T3 (pl) 2018-08-31
EP4706388A2 (de) 2026-03-11
US9089599B2 (en) 2015-07-28
PT3498730T (pt) 2026-02-18
US20140154701A1 (en) 2014-06-05
EP3336102A2 (de) 2018-06-20
EP3498730A1 (de) 2019-06-19
KR101973524B1 (ko) 2019-09-02
EP3498730B1 (de) 2026-01-28
RU2012131296A (ru) 2014-01-27
US20180015185A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
BRPI0925311A2 (de)
BR112012008195A2 (de)
BR112012003062A2 (de)
BRPI0924307A2 (de)
BR112012012396A2 (de)
BR122021004633A2 (de)
BR112012003080A2 (de)
BR112012012487A2 (de)
BRPI0924534A2 (de)
BR112012003853A2 (de)
BR112012009446A2 (de)
BR112012009797A2 (de)
BR112012001263A2 (de)
BR112012014856A2 (de)
BR112012007656A2 (de)
BR112012000159A2 (de)
BR112012002627A2 (de)
BR112012005951A2 (de)
BR112012007654A2 (de)
BR112012007672A2 (de)
BR112012000156A2 (de)
BR112012007671A2 (de)
BRPI0925022A2 (de)
BRPI0924617A2 (de)
BR112012016234A2 (de)